For UK residents only who have been prescribed cemiplimab

Gentleman sitting in chair
Libtayo(cemiplimab)

The information on this page is provided as a support for your treatment with cemiplimab. Please note Libtayo is the brand name for cemiplimab

Couple outside smiling at each other

Cemiplimab and advanced cutaneous squamous cell carcinoma (CSCC)

You can find more about advanced CSCC, cemiplimab, and create personalised support information using our patient portal.

Patient Information Leaflet

Patient Information Leaflet

To access the patient information leaflet on cemiplimab, please click the link below.

Patient Booklet

Patient Booklet

The patient booklet will tell you more about how cemiplimab works, how it's given and possible side effects.

Additional Patient Materials

Additional Patient Materials

For additional information about cemiplimab, please use the link below

Sanofi and Regeneron are collaborating in a global development programme and commercialisation of cemiplimab

Report an Adverse Event

If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme www.mhra.gov.uk/yellowcard By reporting side effects, you can help provide more information on the safety of this medicine.

This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects that you may get. See www.mhra.gov.uk/yellowcard for how to report side effects.